Melanoma, an immunogenic tumor, is the first indication where oncolytic viruses are now becoming part of clinical practice. ONCOS-102, a transgened adenovirus, has shown to act as a primer of relevant tumor targeting immune cells both in preclinical and clinical melanoma studies. Strategies to augment its effectiveness warrant investigation. Combination therapy of ONCOS-102 with the checkpoint inhibitor (CPI) pembrolizumab was evaluated in a quasi-human animal model, the humanized NOG mouse model. A dosing schedule of the combination, beginning the CPI concurrently with the oncolytic viral therapy and continuing the CPI treatment, appeared to induce an abscopal effect in untreated tumor lesions. Concurrent combination therapy with checkpoint inhibitors may improve the induction of antitumor immune responses of ONCOS-102. K E Y W O R D S adenovirus, apoptosis/cell death, cellular effect, disease control, genetics, immune responses, Immunomodulation, recombinant virus, vaccines/vaccine strains, virus classification SUPPORTING INFORMATION Additional supporting information may be found online in the Supporting Information section. How to cite this article: Kuryk L, Møller A-SW, Jaderberg M. Abscopal effect when combining oncolytic adenovirus and checkpoint inhibitor in a humanized NOG mouse model of melanoma.
| INTRODUCTION
Patients with metastatic melanoma (MM) with local or distant tumor nodules have a 5-year survival rate of 63% and 16% to 20%, respectively. 1 Oncolytic adenoviruses execute their antitumor activities by multiple mechanisms that harness the interactions between virus, the immune system, and dysfunctional cell cycle and protein expression in cancer cells. 2 Advantages of oncolytic viruses include selective replication in tumor cells; lysis of tumor cells causing an immunogenic cell death; viral spread that can augment the initial potency of the inoculum; excellent safety profile with minimal effect on surrounding and distant healthy cells and on healthy, rapidly growing cells (eg gastrointestinal tract, hematopoietic system, adult stem cells); and genomic capacity to deliver exogenous proteins. [2] [3] [4] [5] [6] [7] [8] [9] Local secretion of granulocyte macrophage colony stimulating factor (GM-CSF) by oncolytic viruses can increase recruitment, activation, and differentiation of monocytes/macrophages, and can augment local antitumor immune responses. 2, 10, 11 Although the efficacy of oncolytic viruses given monotherapeutically have been proven, 12 additional treatment strategies are needed to develop further improved response rates. 2 Since oncolytic adenoviral treatment induced programmed death-ligand 1 (PD-L1) expression in mesothelioma tumors in a clinical trial, 13 we and others 14 are investigating the combination therapy of oncolytic adenoviruses and checkpoint inhibitors.
Checkpoint inhibitors targeting programmed cell death protein (PD-1) on T cells and other immune cells impede the interaction of
PD-1 with their ligands on tumor cells, thereby reactivating the antitumor immune response. 15, 16 Checkpoint inhibitor therapy (eg. pembrolizumab, nivolumab) of solid tumors has greatly extended the survival of 16% to 20% patients with MM 17 and other solid tumors.
To potentially broaden the responsive patient population, we have
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. chosen to assess the combination therapy of the oncolytic adenovirus ONCOS-102 and the FDA-approved checkpoint inhibitor, pembrolizumab.
Oncolytic viruses (OVs) have the ability to selectively replicate and lyse cancer cells, spreading within the tumor mass and not significantly harming normal cells. OVs can exhibit natural tumor-selective tropism or can be genetically modified for cancer cell-restricted replication. [18] [19] [20] [21] The oncolytic adenovirus ONCOS-102 has three modifications that can augment its efficacy against melanomas. 22, 23 Its chimeric adenoviral 3/5 knob targets the frequently overexpressed membrane protein desmoglein on melanoma cells. Its 24 bp deletion in the E1A gene limits its replication to tumor cells with an altered Rb pathway. 24 Its expression of GM-CSF augments the immunostimulatory microenvironment in the infected tumor. To more closely mimic the induction of human antitumor immune responses, the human hematopoietic stem cell-engrafted NOG mice (hu-NOG mice) 25 were used. Here we modified the dosing schedule to potentially augment the antitumor immune response not only in the treated tumor nodule but also the untreated tumor nodule, with the goal of inducing abscopal effects that are essential for the treatment of MM.
| MATERIALS AND METHODS

| Animals
Animal experiments were compliant with EU Directive (63/2010), adhered to the guidelines from Federation of the European Laboratory Science Association (FELASA), were reviewed and approved by the local ethics committee (01_TransCurebioServices-AB-01).
NOG mice (age, sex, source) were humanized by intravenous injection of 60 000 cord blood human hematopoietic CD34 + stem cells. After 14 weeks, the hu-NOG mice (average % humanization rate (H rate) was 54, Figure S1B ) were engrafted with A2058 tumor cells (2 × 10 6 cells per flank), as described. 26 
| Treatment
ONCOS-102 was grown in A549 cells, harvested, purified as described. 19, 22 The hu-NOG mice were grouped (n = 6-8 mice, 12-16 tumors) for a similar average humanization rate (54%) and mean tumor volume (MTV) of approximately 25 mm 3 . On days 15, 17, and 19, the tumors on the right/left or both sides were injected with 50 µL ONCOS-102 (2.5 × 10 6 VP per tumor) or vehicle (sterile PBS).
The mice also received intravenous administration of vehicle or pembrolizumab (200 or 400 µg) on days 15, 17, 19 and every 3 to 4 days throughout the study (Table 1, Figure 1A ).
| Read-out
Tumor dimensions were measured 3× weekly and the volumes calculated as (length × width 2 /2), as described. Body weight loss also was measured 3× weekly and the percent loss compared to baseline calculated accordingly ( Figure S1A ). presented as mean ± SEM. All P values were two-sided, considered statistically significant when ≤0.05.
| Statistics
| RESULTS
We have previously shown that ONCOS-102 treatment followed by To potentially induce an abscopal effect against A2058-tumorbearing hu-NOG mice, the dosing schedule of the combination therapy of ONCOS-102 and pembrolizumab was revised so that both agents were administered on days 15, 17, and 19 with continuation of pembrolizumab administration every 3 to 4 days thereafter ( Figure 1 and Table 1 ).
On day 26, the MTVs ( Figure 1B and 1D The differences between MTVs among groups were not statistically significant (NS). i.t., intratumoral; i.v., intravenous; MTV, mean tumor volume; Pembro, pembrolizumab; SEM, standard error of the mean these groups were also smaller than the MTVs of the mice treated with ONCOS-102 into two tumors (18 315 mm 3 , group 2). The treatment with pembrolizumab only (either 200 or 400 µg, groups 3 and 4) was less effective than virus alone or combinatory therapies (ONCOS-102 and pembrolizumab) ( Figure 1C and 1E) . The differences between MTVs among groups were not statistically significant. Interestingly, the antitumor responses did not correlate with baseline CD8 + infiltration, PD-L1 status, nor interferon signature. 28 As determined by IHC of planned biopsies, the oncolytic herpes virus increased the infiltration of CD8 + T cells in patients who responded to the combined therapy. 28 Combination therapy comprising the oncolytic New Castle Disease Virus and a concurrently administered murine-specific checkpoint inhibitor-induced abscopal effect on the untreated tumor in a mouse model of bladder cancer. 29 On days 7, 9, 11, and 13 after MD49 bladder tumor cells were injected into the flanks of C57BL/6J mice, the right flank tumors were treated with NDV (10 7 pfu) and the animals concurrently received systemically (intraperitoneally) the anti-PD-L1 or anti-CTLA-4 antibodies. The MTVs of the untreated tumors were reduced, indicative of an abscopal effect. 29 These studies show that information from animal studies may be predictive of responses in patients.
| DISCUSSION
Our in vivo study has several limitations. Since each individual NOG mouse is engrafted with mesenchymal and hematopoietic stem cells from a single human umbilical cord blood donor not shared with other mice, the multiple donors for the hu-NOG mice are likely to have provided a more heterogeneous immune response than inbred mouse strains (allogenic humanization). We expect that the HLA haplotypes of at least some donors were distinct from the A2058 melanoma tumor line. More complete 
